公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms | Kuo, Be-Sheng; Li, Chao-Hung; Chen, Jiun-Bo; Shiung, Yu-Yu; CHIA-YU CHU ; Lee, Chih-Hung; Liu, Yaw-Jen; et al., | The Journal of clinical investigation | 19 | 18 |